- |||||||||| masupirdine (SUVN-502) / Suven Life Sci
Journal: Drug Development. (Pubmed Central) - Jan 12, 2025 P2a, P3 The Phase-3 study results may inform the therapeutic utility of masupirdine for the treatment of Alzheimer's agitation. Phase-3 study data readout is anticipated in Q1/Q2 2025.
- |||||||||| ropanicant (SUVN-911) / Suven Life Sci
Effect of Ropanicant (SUVN-911), an ?4?2 Receptor Antagonist in Animal Models of Depression (Salon 4) - Apr 29, 2024 - Abstract #ASCP2024ASCP_259; P2 Learning Objectives 1.Evaluate the non-clinical efficacy of ropanicant an ?4?2 receptor antagonist in animal models of depression. 2.To understand the differentiating features of ropanicant over current standards of care with respect to onset of action and side effects profile
- |||||||||| masupirdine (SUVN-502) / Suven Life Sci
Masupirdine (SUVN-502), a pure 5-HT6 receptor antagonist: Rationale for evaluation in patients with agitation in dementia of Alzheimer's type (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_7246; P2a, P3 In addition, masupirdine significantly modulated levels of dopamine and norepinephrine in brain at a dose of 10 mg/kg, s.c. The post hoc analysis of the Phase-2 study (NCT02580305) in patients with moderate AD suggested treatment with masupirdine at 50 mg and 100 mg significantly decreased the agitation/aggression score from Week 13 to Week 26 suggesting potential treatment effects of masupirdine on agitation/aggression symptoms. To explore the beneficial effects, masupirdine is currently being evaluated as a monotherapy in a global Phase-3 study for the potential treatment of agitation in participants with dementia of Alzheimer's type (NCT05397639).
- |||||||||| masupirdine (SUVN-502) / Suven Life Sci, Rexulti (brexpiprazole) / Lundbeck, Otsuka
Journal: A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease. (Pubmed Central) - Apr 21, 2023 Clinical trials remain underway utilizing both novel and repurposed agents to address symptoms of agitation in AD. With increasing understanding of the neurobiological mechanisms that fuel the development of agitation in AD, the use of enhanced trial design and conduct, advanced statistical approaches, and accelerated pathways for regulatory approval, we are advancing closer to having safe and efficacious treatment options for agitation in AD.
|